Introduction
Aplasia cutis congenita (ACC) is an uncommon side effect related to the use of methimazole or c a rbimazole during early pregnancy. The latter drug is rapidly bioactivated to methimazole (Fig. 1) . In the literature, since 1972, we found 24 cases of ACC related to maternal antithyroid drug therapy. In France, no case has been reported by the National Center of Pharmacovigilance since 1985. We report a n e w b o rn with a case of ACC and multiple somatic malformations.
Case Repor t
A 39-year-old-woman without significant past history had Graves disease without exophthalmos. The initial laboratory tests revealed several thyroidstimulating hormone determinations below the limit of detection. The free T4 was 340 nM (normal value 148 nM). The serum antithyroid-stimulating horm o n e receptor autoantibodies were 43 IU/L (normal value 4 IU/L). She was treated with carbimazole 60 mg/day. A diagnosis of pregnancy was made after 12 weeks of treatment by carbimazole. She was treated with propylthiouracil, 300 mg/day, for the remainder of the pregnancy. The karyotype, made because of the mother's age, was 46XX. At birth, the female infant had a single area of alopecia, 7-x 2 -c m , on the vertex (Fig. 2) , transient hypothyroidism, and a dysmorphic syndrome (flat face, low-set ears, upper lip retraction (Fig. 3) , a xiphoid funnel, and claw-like fingers with a low-set fifth finger). Skull radiographs and a computerized tomographic scan of the brain were normal. At 1 year, the alopecia was successfully treated surgically.
Discussion
Histologically, ACC is defined as the localized absence of skin (epidermis, dermis, and occasionally subcutis). It may be associated with underlying cranial bone defects. There is neither inflammation nor d y splasia. Since the first report by Cordon in 1767, m o re than 500 cases have been described. According to Van Dijke et al. 1 , it affects 0.03% of newborns. Aplasia cutis congenita may be associated with epidermolysis bullosa, placental abnormalities ( l a c k of resorption, tears, or abnormal amniotic bands during delivery), viral infections (herpes simplex, varicella), toxins (heroin, cocaine), and, occasionally, intrauterine exposure to methimazole, prostaglandin E 1 analogs, valproic acid, and misoprostol.
Importantly, in the literature, 24 cases of ACC have been described subsequent to exposure to methimazole or carbimazole during pre g n a n c y ( Table 1) . In most cases, these drugs have been administered during the first 2 months of pregnancy and then often replaced by propylthiouracil until delivery. The newborns had one or more areas of ACC, occasionally associated with the absence of underlying bone (two infants) 4, 5 . Sometimes, the skin defects had closed spontaneously within a few months. Indeed, some believe that cases of ACC may be missed because the healing has occurred during intrauterine life. Four newborns (two sets of twins) had malformations, mostly related to umbilical immaturity, such as patent urachus. Choanal atresia, esophageal atresia, or tracheoesophageal fistulae are also described 6, 7 .
The precise cause of ACC is unknown 8, 9 . There is no apparent link to maternal age (the mothers were between ages 20 and 40 years) and no relation to dose (ranging from 5-60 mg/day; 15 mg/day in most cases). The reported associated malformations (five cases) have suggested that there might be a genetic predisposition to ACC, which is revealed by methimazole. Other malformations have been described after treatment with methimazole during pregnancy. These include choanal atresia, intestinal anomalies (imperforate anus, esophageal atresia), cardiovascular defects, and facial anomalies 10, 12 . Johnsson et al. 13 reported a severe case associating many of these later malformations. Thyroid status may play a role. It is known that the frequency of malformations is greater for infants born to mothers with hyperthyroidism (3%-6% vs. 0.2% for the infants born to mothers with euthyroidism) 9 , 1 4 . These m a l f o rmations include omphalocele, imperforate anus, anencephaly, malformation of the earlobe, harelip, and polydactyly; the same as those reported after treatment by methimazole. In our case, the mother had hyperthyroidism during the embryogenesis.
Some studies investigated the specific re l a t i o n s h i p between ACC and methimazole therapy. At the chrom o s o m a l a b n o rmalities and also various somatic malformation syndromes 2 . Frieden 3 developed a classification for the disease. Observed malform a t i o n s include hypertelorism, microphthalmia, micro c e p h a l y , ear malformations, polydactyly, genital hypoplasia, renal abnormalities, and mental deficiency. The c h romosomal abnormalities, which are identified on occasion, include a 4p deletion (Wolf-Hischhorn syndrome), tetrasomy 12, or trisomy 13. In some well-identified syndromes, the mode of transmission has been established to be autosomal dominant University Hospital of Amsterdam, during a period of 27 years, 48,057 mothers gave birth to 49,091 newborns. Twenty-five children had ACC (0.05%), which was confined to the scalp in 0.03% (13 infants). None of the mothers had used antithyroid drugs during pregnancy 1 . Momotani et al. 1 4 e v a l u a t e d 243 infants whose mothers had been treated with methimazole during pregnancy. Two had malformations (omphalocele, abnormalities of the earlobe), but none had scalp defects. These malformations are reported in 1.7% of infants whose mothers received methimazole and had hyperthyroidism and in no infants whose mothers were t reated by m e t h imazole but were euthyroid. One study re p o r t e d the three-fold increase in the frequency of this anomaly in certain regions of Spain where there was illegal use of methimazole as a fattening agent in animal feed 1 5 .
The latest study from Wing et al. 16 concluded that propylthiouracil and methimazole are equally safe. The incidence of major anomalies in infants exposed to these drugs is not different from that of the general population. The incidence was 3% (3 of 99) in infants of propylthiouracil-treated mothers. The mothers of these infants had hyperthyroidism during the period of embryogenesis. These infants had pulmonic stenosis, ventricular septal defect, and patent ductus arteriosus. In infants of methimazolet reated mothers, the incidence of anomalies was 2.7% (1 of 36 infants had a congenital inguinal hernia; his mother had euthyroidism). No case of ACC was found.
No scalp defects have been observed in infants Methimazole ( whose mothers had been treated only with p ropylthiouracil, even though this drug is administered more frequently than methimazole. Is this disparity caused by diff e rences in their metabolism and/or passage across the placenta? Methimazole, which exhibits negligible pro t e i n binding, is lipid-soluble. It crosses the placenta rapidly by a simple diffusion process. Appro x i m a t e l y 0.9% of the cumulative dose administered to the mother during her pregnancy can be found in the fetal serum. In contrast, propylthiouracil is bound to protein (60%-70%) and is less lipid-soluble. Its metabolism is rapid. The drug is quickly excreted as glucuronic acid conjugates. Thus, the placental transfer of propylthiouracil may be limited. More recently, a study was performed on the isolated, perfused, term-human placenta. In this study, the transfer of low and high doses of propylthiouracil and methimazole from the maternal to the fetal c i rculation was investigated, with or without the addition of bovine albumin. No diff e rence was found between the transfer of the drugs, the elimination rate constants, or the clearances 1 7 . In this respect, as far as the fetal hypothyroidisminducing potential is concerned, there is apparently no diff e rence between propylthiouracil and m e t h imazole 14 . The apparent relationship between ACC and methimazole is not certain. Because of the rarity of ACC, a prospective clinical study will be d i fficult to perform. It is also uncertain whether methimazole is harmful only if administered during the first trimester. Nevertheless, among cases associated with the maternal administration of antithyroid drugs during early pregnancy, the relationship to methimazole (or carbimazole) is striking. Accordingly, we recommend the avoidance of these two drugs during pregnancy. In all women of child-bearing age with hyperthyroidism, a pregnancy test should be performed before therapy. If the test result is negative, contraception should be initiated. F u r t h e rm o re, because propylthiouracil ingestion during early pregnancy has, to our knowledge, never been associated with ACC, we recommend the exclusive use of this antithyroid drug for the woman with hyperthyroidism who is already pregnant.
